Bristol-Myers Squibb Company reports that an open-label, randomized Phase III study evaluating Opdivo (nivolumab) versus docetaxel in previously treated patients with advanced non-squamous non-small cell lung cancer was stopped early because the study met its endpoint, demonstrating superior overall survival in patients receiving Opdivo compared to the control arm.

“The results mark the second time Opdivo has demonstrated a survival advantage in lung cancer,” said Michael Giordano, senior vice president, Head of Development, Oncology, Bristol-Myers Squibb. “Through our Opdivo clinical development program, we seek to bring the potential for long-term survival to a broad range of patients, across lines of therapy and stages of disease.”